(Q37606744)

21 August 2017

1 reference

title

Resistance to targeted therapy in renal-cell carcinoma (English)

1 reference

21 August 2017

Brian I Rini

1

1 reference

21 August 2017

Michael B Atkins

series ordinal

2

1 reference

21 August 2017

publication date

1 October 2009

1 reference

Lancet Oncology Commission

21 August 2017

published in

1 reference

21 August 2017

volume

10

1 reference

21 August 2017

issue

10

1 reference

21 August 2017

page(s)

992-1000

1 reference

Identification of the von Hippel-Lindau disease tumor suppressor gene

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970240-2

7 January 2021

Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970240-2

7 January 2021

Oxygen tension regulates the expression of the platelet-derived growth factor-B chain gene in human endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970240-2

7 January 2021

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970240-2

7 January 2021

Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970240-2

7 January 2021

Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970240-2

7 January 2021

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970240-2

7 January 2021

von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970240-2

7 January 2021

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970240-2

7 January 2021

Modes of resistance to anti-angiogenic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970240-2

7 January 2021

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970240-2

7 January 2021

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970240-2

7 January 2021

Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970240-2

7 January 2021

Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970240-2

7 January 2021

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970240-2

7 January 2021

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970240-2

7 January 2021

Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970240-2

7 January 2021

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970240-2

7 January 2021

Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970240-2

7 January 2021

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970240-2

7 January 2021

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970240-2

7 January 2021

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970240-2

7 January 2021

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970240-2

7 January 2021

Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970240-2

7 January 2021

Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970240-2

7 January 2021

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970240-2

7 January 2021

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970240-2

7 January 2021

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970240-2

7 January 2021

Systemic overexpression of angiopoietin-2 promotes tumor microvessel regression and inhibits angiogenesis and tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970240-2

7 January 2021

Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970240-2

7 January 2021

Angiopoietin-2 stimulates breast cancer metastasis through the alpha(5)beta(1) integrin-mediated pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970240-2

7 January 2021

Positive feedback regulation between MMP-9 and VEGF in human RPE cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970240-2

7 January 2021

Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970240-2

7 January 2021

Resistance to EGF-R (erbB-1) and VEGF-R modulating agents

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970240-2

7 January 2021

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970240-2

7 January 2021

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970240-2

7 January 2021

Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970240-2

7 January 2021

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970240-2

7 January 2021

Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970240-2

7 January 2021

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970240-2

7 January 2021

Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970240-2

7 January 2021

A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970240-2

7 January 2021

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970240-2

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970240-2

7 January 2021

10.1016/S1470-2045(09)70240-2

Identifiers

DOI

1 reference

21 August 2017

1 reference